Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Summary
This is a single-centre, observational, prospective and exploratory study, which involves the use of human tissues from patients affected by Relapsed/Refractory classic Hodgkin Lymphoma treated with pembrolizumab at the Departmental Diagnosis and Therapy program for chronic lymphoproliferative syndromes of the IRCCS AOU of Bologna. Peripheral blood samples will be used for the study and will be taken: * before starting treatment with pembrolizumab. * undergoing therapy with pembrolizumab (cycle 2 (C2), C3, C4, C8, C12).
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
40
Start Date
2024-08-01
Completion Date
2027-02-01
Last Updated
2024-12-13
Healthy Volunteers
No
Conditions
Locations (1)
IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, Italy